Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy

J Dtsch Dermatol Ges. 2020 Feb;18(2):136-139. doi: 10.1111/ddg.13991. Epub 2019 Dec 9.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Female
  • Humans
  • Imidazoles / adverse effects*
  • Immunotherapy / adverse effects
  • Ipilimumab / adverse effects
  • Melanoma / drug therapy*
  • Nivolumab / adverse effects
  • Oximes / adverse effects*
  • Posterior Leukoencephalopathy Syndrome / etiology*
  • Pyridones / adverse effects*
  • Pyrimidinones / adverse effects*
  • Skin Neoplasms / drug therapy*

Substances

  • Imidazoles
  • Ipilimumab
  • Oximes
  • Pyridones
  • Pyrimidinones
  • Nivolumab
  • trametinib
  • dabrafenib